Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.
J Neuroimmunol
; 113(1): 109-18, 2001 Feb 01.
Article
de En
| MEDLINE
| ID: mdl-11137582
ABSTRACT
A complete prevention of clinical experimental autoimmune myasthenia gravis (EAMG) was observed in lymphotoxin (LT)-alpha deficient (LT-alpha(-/-)) mice compared to LT-alpha(+/+) mice when immunized with acetylcholine receptor. However, only a partial prevention of clinical EAMG incidence was observed in LT-beta(-/-) mice compared to LT-beta(+/+) mice. LT-alpha(-/-)and LT-beta(-/-) mice had lower mean titers of total IgG, IgG(1), IgG(2a) and IgG(2b) and higher or equal mean titers of IgM anti-AChR antibodies compared to controls. Therefore, LT-alpha(-/-)and LT-beta(-/-) AChR immunized mice are capable of mounting a primary (IgM) humoral immune response to AChR, but are less capable of switching to the pathogenic anti-AChR IgG isotypes. LT could play a significant role in the pathogenesis of myasthenia gravis.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Lymphotoxine alpha
/
Récepteurs cholinergiques
/
Myasthénie auto-immune expérimentale
Limites:
Animals
Langue:
En
Journal:
J Neuroimmunol
Année:
2001
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique